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The prevalence of nonalcoholic fatty liver disease (NAFLD) in the non-obese population has
increased and NAFLD is not always recognized in individuals with metabolic syndrome
(MS). The risk of cirrhosis is higher in patients having NAFLD with elevated alanine amino-
transferase (ALT) levels than in those having NAFLD with normal ALT levels.
Objective
To measure the differences in clinical factors associated with NAFLD having elevation of
ALT among subjects with Non-MS, Pre-MS, and MS, and to measure differences in metabo-
lites between MS subjects with and without NAFLD having elevation of ALT.
Methods
Among 7,054 persons undergoing health check-ups, we included 3,025 subjects who met
the selection criteria. We measured differences in clinical factors for NAFLD having eleva-
tion of ALT among subjects with Non-MS, Pre-MS, and MS, and compared metabolites
between subjects with and without NAFLD having elevation of ALT in 32 subjects with MS.
Results
The prevalence of NAFLD and NAFLD having elevation of ALT was significantly progres-
sively greater in subjects with Non-MS, Pre-MS, and MS (p <0.001, respectively). In the
Non-MS group, there were significant differences between subjects with and without
NAFLD having elevation of ALT with respect to body mass index (BMI), high-density lipopro-
tein cholesterol (HDL-C), low-density lipoprotein cholesterol, hemoglobin A1c, uric acid,
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aspartate aminotransferase (AST); In the Pre-MS group, there were significant differences
in BMI, hypertension, AST, and gamma-glutamyl transpeptidase (GGT); In the MS group,
there were significant differences in HDL-C, impaired glucose tolerance, AST, and GGT.
There were significant differences in levels of metabolites of nicotinamide, inosine, and ace-
tyl-L-carnitine between MS subjects with and without NAFLD having elevation of ALT (all
p <0.05).
Conclusions
Although NAFLD having elevation of ALT is important for development of NAFLD, differ-
ences in factors associated with NAFLD having elevation of ALT at various stages of MS
should be considered. Additionally, several metabolites may play roles in the identification
of risk for NAFLD in individuals with MS.
Introduction
Despite the fact that the increase in prevalence of metabolic syndrome (MS) that is strongly
associated with nonalcoholic fatty liver disease (NAFLD) has been problematic in gastroenter-
ology, NAFLD is not always recognized in individuals with MS [1–3]. Persons who are easy to
become NAFLD and those who are hard to become NAFLD may exist in individuals who
belong to the same MS. Additionally, the prevalence of NAFLD in the non-obese population
has gradually increased in Japan, and not low [4, 5]. Generally, NAFLD is diagnosed using the
presence of fatty liver regardless of assessment of liver enzymes in the context of medical
check-ups and NAFLD having elevation of liver enzyme and NAFLD having standard values
of liver enzyme have been treated in the same way; nevertheless, patients with NAFLD and ele-
vation of alanine aminotransferase (ALT) are at higher risk for cirrhosis than those with
NAFLD and normal ALT values [6]. However, there is few reports about NAFLD having eleva-
tion of ALT levels at various stages of MS. The aim of this study was to measure the differences
in clinical factors associated with NAFLD having elevation of ALT among subjects with Non-
MS, Pre-MS, and MS, and to measure differences in metabolites between MS subjects with
and without NAFLD having elevation of ALT.
Methods
Study design and subjects
This cross-sectional study was conducted among 7,054 subjects residing in the Shikoku region,
Japan, and undergoing regular health check-ups at Shikoku Central Hospital of the Mutual
Aid Association of Public School Teachers between April 2018 and March 2019. Among 7,054
subjects, 4,029 subjects were excluded for fulfilling any of the following criteria: (1) positivity
for markers of hepatitis B virus infection (hepatitis B surface antigen) and/or hepatitis C virus
infection (anti-hepatitis C virus antibodies); (2) alcohol consumption of�20 g/day in males or
alcohol consumption of�10 g/day in females; (3) absence of abdominal ultrasonography; (4)
history of liver surgery; and (5) current or previous medication for liver disease. Finally, 3,025
subjects were enrolled (Fig 1). The study protocol was approved by the Ethics Committee of
Shikoku Central Hospital, and all procedures were performed in accordance with the Declara-
tion of Helsinki. All subjects were informed that their clinical data might be retrospectively
analyzed, and informed consent was obtained.
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Diagnosis of MS
The diagnostic criteria for MS adopted by the World Health Organization (WHO) or the adult
treatment panel (ATP) III criteria are used worldwide. However, we adopted the MS criteria
proposed by the joint committee of eight Japanese medical societies in 2005 because all sub-
jects in our study were Japanese [7]. Component factors of MS criteria are waist circumference
(WC) must exceed 85 cm for males or 90 cm for females, and the presence of two or more of
the following: (1) dyslipidemia: high-density lipoprotein cholesterol (HDL-C) <40 mg/dl,
and/or triglycerides (TG)�150 mg/dl, or medication for dyslipidemia; (2) impaired glucose
tolerance (IGT): fasting plasma glucose (FPG)�110 mg/dl or medication for diabetes; and (3)
hypertension: blood pressure� 130/85 mmHg or medication for hypertension.
We designated individuals who fulfilled these criteria as the MS group. Individuals who did
not fulfill above MS criteria were divided into two groups as follows: The Non-MS group was
defined as individuals having no component of MS; The Pre-MS group was defined as
Fig 1. Participant flow of individuals undergoing check-ups. HBsAg, hepatitis B surface antigen; HCVAb, hepatitis C antibody.
https://doi.org/10.1371/journal.pone.0238388.g001
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individuals having more than 85 cm of WC for males or 90 cm for females and one component
of MS.
Physical examination and serum biochemistry
Body weight (BW) and height were obtained from all subjects. BW was measured to the near-
est 0.1 kg, and height was measured to the nearest 0.1 cm. The body mass index (BMI) was cal-
culated as the weight (in kilograms) divided by the square of the height (in meters) expressed
in kg/m2. WC was measured at the umbilical level by a laboratory technician. Venous blood
samples were taken from all subjects in the morning after 12 hours of overnight fasting. Clini-
cal laboratory tests included aspartate aminotransferase (AST), ALT, gamma-glutamyl trans-
peptidase (GGT), total cholesterol (T-CHO), HDL-C, TG, low-density lipoprotein cholesterol
(LDL-C), uric acid (UA), FPG, and hemoglobin A1c (HbA1c). Ferritin, insulin, and type IV
collagen 7S were measured among 34 subjects with MS during 2018 April, and the homeostasis
model assessment of insulin resistance (HOMA-IR) and NAFIC score and the Fibrosis (FIB)-4
indexes were assessed [8–12]. ALT elevation was defined as level more than 30 IU/L.
Assessment of ultrasonography
Standard abdominal ultrasonography was performed by trained technicians in the morning
with the subjects fasting. The HI-VISION Avius1 and ALOKA ARIETTA 850 (Hitachi Ltd.,
Tokyo, Japan) platforms with 6-MHz convex-array probes were used for ultrasonography. The
diagnostic criteria for fatty liver on ultrasonography were as follows: echo contrast between the
liver and the renal cortex, liver brightness, blurring of liver vessels, and/or deep attenuation
[13, 14]. In our study, fatty liver with alcohol consumption of less than 20 g/day in males or
alcohol consumption of less than 10 g/day in females and without chronic liver diseases such
as hepatitis B, hepatitis C, and liver disease related with autoimmune was defined as NAFLD.
Metabolomics and sulfur metabolomics
Sera from 34 subjects with MS during 2018 April were obtained by centrifugation of blood
samples for 10 min at 1500× g at 4˚C, and was stored at –80˚C until use. Metabolomics follow-
ing the primary metabolism method was performed using liquid chromatography coupled to a
tandem mass spectrometry (LC-MS/MS) (Nexera UHPLC system with on-line LC-MS 8040,
Shimadzu Corporation, Kyoto, Japan). Briefly, 10 μL of serum was added to 110 μL methanol
containing internal standards at 0˚C to inactivate native enzymes. After centrifugation, the
upper aqueous layer of the separated solution was desiccated using a centrifugal evaporator.
Thereafter, 60 μL of water was added, and the solution was centrifuged. We used 10 μL from
the upper aqueous layer as the metabolomics sample. Sulfur metabolomics was performed by
the Sulfur Index service in Japan (http://www.euglena.jp/sulfurindex/; Euglena Co. Ltd.,
Tokyo, Japan). The sulfur index uses a technology where metabolites are detected as S-bimanyl
derivatives by LC-MS/MS (Shimadzu (Nexera UHPLC system with on-line LC-MS 8040, Shi-
madzu, Corporation, Kyoto, Japan) as described previously [15, 16]. Briefly, the sulfur-con-
taining compounds in the samples were extracted by adding methanol and converting to
fluorescent derivatives with monobromobimane. The levels of the target metabolites were
determined from the peak area in the mass chromatography, monitoring each mass-to-charge
ratio of the individual target, and represented as relative amounts (relative areas) after normal-
ization based on the peak area of the internal standard (D-camphor-10-sulfonic acid). We
measured 101 primary metabolites such as amino acids, organic acids, and the like, and a total
of 52 metabolites were obtained from subjects with MS. We measured 90 sulfur metabolites
and found a total of 17 sulfur metabolites in subjects with MS.
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Statistical analysis
Quantitative data, including subject baseline characteristics, were expressed as the
mean ± standard deviation (SD). P-values of less than 0.05 were considered statistically signifi-
cant. The χ2-test or Mann–Whitney U-test was used for comparisons between the two groups.
The m × n χ2-test or Kruskal–Wallis test was used to analyze differences among three groups.
If the Kruskal–Wallis test revealed differences between the groups, then post-hoc pairwise
comparisons were performed using the Mann–Whitney U test with Bonferroni correction.
Correlations between variables were assessed by calculating Spearman rank correlation coeffi-
cients. Factors with significant influence on the prevalence of NAFLD having elevation of ALT
were determined using univariate analysis. All parameters that had P-values of less than 0.05
by univariate analysis were assessed using stepwise multivariate logistic regression analysis
adjusted for age and gender. The odds ratio (OR) and 95% confidence interval (CI) were ana-
lyzed for each variable. All statistical analyses were performed using MedCalc Statistical Soft-
ware for Windows (MedCalc Software; Ostend, Belgium).
Results
Baseline characteristics among Non-MS, Pre-MS, and MS groups
The baseline characteristics of 3,025 subjects are shown in Table 1. The prevalence of Non-MS, Pre-
MS, and MS groups was 74.3%, 11.9%, and 13.8%, respectively. The proportion of males, age, BMI,
and WC were significantly high in order of MS group, Pre-MS group, Non-MS group (p< 0.001,
p<0.05, p<0.05, and p<0.05, respectively). The prevalence of smoker and drinker in MS group
and Pre-MS group were significantly higher than in Non-MS group (p< 0.001 and p<0.05,
respectively). The prevalence of hypertension, SBP, and DBP were significantly high in order of MS
group, Pre-MS group, Non-MS group (p< 0.001, p<0.05, and p<0.05, respectively). The preva-
lence of dyslipidemia, TG, and LDL-C were significantly high in order of MS group, Pre-MS group,
Non-MS group (p< 0.001, p<0.05, and p<0.05, respectively), and HDL-C was significantly low
in order of MS group, Pre-MS group, Non-MS group (p<0.05). FPG and HbA1c were significantly
high in order of MS group, Pre-MS group, Non-MS group (p<0.05 for both). The prevalence of
IGT was significantly higher in MS group than in Pre-MS group and Non-MS group (p<0.001).
UA was significantly high in order of MS group, Pre-MS group, Non-MS group (p<0.05). ALT,
AST, GGT, and the prevalence of NAFLD were significantly high in order of MS group, Pre-MS
group, Non-MS group (p< 0.05, p<0.05, p<0.05, and p<0.001, respectively).
Comparison of the prevalence of NAFLD and NAFLD having elevation of
ALT among Non-MS, Pre-MS, and MS groups
The comparison of the prevalence of NAFLD among the Non-MS, Pre-MS, and MS groups is
shown in Fig 2A. The prevalence of NAFLD in Non-MS group, Pre-MS group, and MS group
were 18.6% (417/2,246), 67.0% (242/361), and 82.1% (343/418), respectively. There was a sig-
nificant difference in the prevalence of NAFLD among the three groups (p< 0.001). The prev-
alence of NAFLD was higher in the MS group vs. the Pre-MS group and the Non-MS group
(p< 0.001 and p< 0.001, respectively), and the prevalence of NAFLD was significantly higher
in the Pre-MS group than in the Non-MS group (p<0.001).
A comparison of the prevalence of NAFLD having elevation of ALT among Non-MS, Pre-
MS, and MS groups is shown in Fig 2B. The prevalence of NAFLD having elevation of ALT in
Non-MS, Pre-MS, and MS groups were 5.1% (115/2,246), 28.8% (104/361), and 44.3% (185/
418), respectively. There were significant differences in the prevalence of NAFLD having eleva-
tion of ALT among the three groups (p< 0.001). The prevalence of NAFLD having elevation
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of ALT was higher in the MS group than in the Pre-MS group and Non-MS group (p< 0.001
and p< 0.001, respectively), and the prevalence of NAFLD having elevation of ALT was higher
in Pre-MS group than in the Non-MS group (p<0.001).
Factors associated with NAFLD having elevation of ALT among Non-MS,
Pre-MS, and MS groups
Results of univariate analysis for factors associated with NAFLD having elevation of ALT
among Non-MS group, Pre-MS group, and MS group are shown in Table 2. In the Non-MS
group, univariate analysis showed that gender, BMI, WC, SBP, DBP, hypertension, T-CHO,
TG, HDL-C, LDL-C, dyslipidemia, FPG, HbA1c, IGT, UA, AST, and GGT were significantly
associated with NAFLD having elevation of ALT. In the Pre-MS group, univariate analysis
showed that gender, age, BMI, WC, hypertension, HDL-C, dyslipidemia, FPG, HbA1c, UA,
Table 1. Baseline characteristics among Non-MS, Pre-MS, and MS groups (n = 3,025).
Total Non-MS Pre-MS MS p-value
subjects group group group
(n = 3,025) (n = 2,246) (n = 361) (n = 418)
Gender (F/M) 1,739/1,286 1506/740 125/236 108/310 < 0.001˚(�<0.001, §<0.001, ˚<0.001)
Age (years) 52.0 ± 9.4 51.2 ± 9.7a 53.5 ± 8.1b 55.4 ± 7.2c < 0.001
BMI (kg/m2) 23.6 ± 3.9 22.1 ± 2.8a 27.2 ± 3.4b 28.2 ± 3.8c < 0.001
WC (cm) 83.2 ± 10.4 79.2 ± 7.7a 93.7 ± 7.2b 96.1 ± 8.5c < 0.001
Smoker, n (%) 270 (8.9%) 155 (6.9%) 52 (14.4%) 63 (15.1%) < 0.001 (�<0.001, ˚<0.001)
Drinker, n (%) 1,278 (42.2%) 906 (40.3%) 176 (48.8%) 196 (46.9%) < 0.005 (�<0.05, ˚<0.005)
SBP (mmHg) 124 ± 17 120 ± 16a 132 ± 16b 137 ± 16c < 0.001
DBP (mmHg) 77 ± 13 74 ± 11a 83 ± 11b 88 ± 12c < 0.001
Hypertension, n (%) 1,276 (42.2%) 649 (28.9%) 240 (66.5%) 387 (92.6%) < 0.001 (�<0.001, §<0.001, ˚<0.001)
T-CHO (mg/dL) 210.8 ± 35.0 210.7 ± 34.8 213.1 ± 33.2 209.1 ± 37.3 0.253
TG (mg/dL) 104.7 ± 69.3 89.7 ± 51.1a 121.5 ± 56.6b 170.7 ± 110.2c < 0.001
HDL-C (mg/dL) 66.5 ± 17.4 70.5 ± 17.0a 57.2 ± 12.3b 53.0 ± 13.3c < 0.001
LDL-C (mg/dL) 128.7 ± 30.6 126.9 ± 30.1a 137.0 ± 29.4b 131.2 ± 32.6c < 0.001
Dyslipidemia, n (%) 797 (26.3%) 341 (15.2%) 103 (28.5%) 353 (84.4%) < 0.001 (�<0.001, §<0.001, ˚<0.001)
FPG (mg/dL) 100.3 ± 16.8 96.7 ± 11.2a 100.9 ± 9.7b 118.7 ± 29.7c < 0.001
HbA1c (%) 5.6 ± 0.6 5.5 ± 0.4a 5.6 ± 0.4b 6.2 ± 1.0c < 0.001
IGT, n (%) 445 (14.7%) 193 (8.6%) 18 (5.0%) 234 (56.0%) < 0.001 (�<0.001, §<0.001)
UA (mg/dL) 5.0 ± 1.3 4.8 ± 1.2a 5.8 ± 1.3b 5.9 ± 1.3c < 0.001
ALT (IU/L) 23.0 ± 16.3 19.3 ± 11.4a 29.5 ± 17.7b 37.0 ± 25.3c < 0.001
AST (IU/L) 23.7 ± 8.9 22.3 ± 6.6a 25.4 ± 8.8b 29.6 ± 15.1c < 0.001
GGT (IU/L) 30.4 ± 29.9 26.2 ± 27.0a 36.6 ± 27.9b 48.0 ± 37.5c < 0.001
NAFLD, n (%) 1,002 (33.1%) 417 (18.6%) 242 (67.0%) 343 (82.1%) < 0.001 (�<0.001, §<0.001, ˚<0.001)
Data represent the mean ± standard deviation (SD) and number for categorical variables.
P-values are based on the m × n χ2-test or Kruskal Wallis test. If the Kruskal Wallis test revealed differences between the groups, then post-hoc pairwise comparisons
were performed using the Mann-Whitney U test with Bonferroni correction. Different letters (a, b, c) indicate a significant difference at the 0.0166 (0.05/3) level. The χ2-
test was used for comparisons of number for categorical variables between the two groups (�MS group vs. non-MS group, §MS group vs. pre-MS group, ˚pre-MS group
vs. non-MS group). Significant is at the 5% level.
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; DBP, diastolic blood pressure; F, female; FPG, fasting plasma glucose; GGT,
gamma-glutamyl transpeptidase; HbA1c, hemoglobin A1c; HDL-C, high-density lipoprotein cholesterol; IGT, impaired glucose tolerance; LDL-C, low-density
lipoprotein cholesterol; M, male; MS, metabolic syndrome; NAFLD, nonalcoholic fatty liver disease; SBP, systolic blood pressure; T-CHO, total cholesterol; TG,
triglyceride; UA, uric acid; WC, waist circumference. Drinker: < 20 g/day of alcohol in male; < 10 g/day of alcohol in female.
https://doi.org/10.1371/journal.pone.0238388.t001
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AST, and GGT were significantly associated with NAFLD having elevation of ALT. In the MS
group, univariate analysis showed that gender, age, BMI, WC, TG, HDL-C, HbA1c, IGT, UA,
AST, and GGT were significantly associated with NAFLD having elevation of ALT.
Fig 2. Comparison of the prevalence of NAFLD and NAFLD having elevation of ALT among the Non-MS, Pre-MS, and MS
groups. A Comparison of the prevalence of NAFLD among the Non-MS, Pre-MS, and MS groups. B Comparison of the
prevalence of NAFLD having elevation of ALT among the Non-MS, Pre-MS, and MS groups. The gray bar indicates the
prevalence of NAFLD. The black bar indicates the prevalence of NAFLD having elevation of ALT. ALT, alanine
aminotransferase; MS, metabolic syndrome; NAFLD, nonalcoholic fatty liver disease; �P< 0.001.
https://doi.org/10.1371/journal.pone.0238388.g002
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Independent predictors of NAFLD having elevation of ALT among Non-
MS, Pre-MS, and MS groups
Results of multivariate analysis for independent predictors of NAFLD having elevation of ALT
among Non-MS group, Pre-MS group, and MS group are shown in Table 3. In the Non-MS
group, BMI, LDL-C, HbA1c, UA and AST were significant independent predictors of
increased prevalence of NAFLD having elevation of ALT, whereas HDL-C contributed signifi-
cantly and independently to decreased prevalence of NAFLD having elevation of ALT. In the
Pre-MS group, BMI, AST, and GGT were significant and independent predictors of increased
prevalence of NAFLD having elevation of ALT, whereas hypertension contributed significantly
and independently to decreased prevalence of NAFLD having elevation of ALT. In the MS
group, IGT, AST, and GGT were significant and independent predictors of increased preva-
lence of NAFLD having elevation of ALT, whereas HDL-C contributed significantly and inde-
pendently to decreased prevalence of NAFLD having elevation of ALT.
Comparison of baseline characteristics between subjects with and without
NAFLD having elevation of ALT in 32 subjects with MS
A comparison of the baseline characteristics between subjects with and without NAFLD hav-
ing elevation of ALT in 32 subjects with MS are shown in Table 4. The mean age in subjects
Table 2. Results of univariate analysis for factors associated with NAFLD having elevation of ALT among Non-MS, Pre-MS, and MS groups.
Non-MS group Pre-MS group MS group
Factor OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value
Gender 4.880 (3.256–7.315) < 0.001 2.901 (1.678–5.016) < 0.001 1.753 (1.112–2.765) < 0.05
Age (years) 1.000 (0.981–1.020) 0.999 0.950 (0.923–0.978) < 0.001 0.954 (0.927–0.981) < 0.005
BMI (kg/m2) 1.417 (1.329–1.511) < 0.001 1.123 (1.050–1.200) < 0.001 1.165 (1.099–1.235) < 0.001
WC (cm) 1.139 (1.110–1.169) < 0.001 1.046 (1.014–1.079) < 0.005 1.067 (1.040–1.095) < 0.001
SBP (mmHg) 1.019 (1.008–1.031) < 0.001 0.995 (0.981–1.010) 0.498 0.998 (0.986–1.010) 0.715
DBP (mmHg) 1.036 (1.020–1.052) < 0.001 1.000 (0.980–1.021) 0.999 1.013 (0.997–1.030) 0.123
Hypertension 1.824 (1.244–2.674) < 0.005 0.551 (0.344–0.882) < 0.05 1.108 (0.528–2.324) 0.787
T-CHO (mg/dL) 1.007 (1.002–1.012) < 0.01 0.998 (0.991–1.005) 0.610 1.001 (0.995–1.006) 0.836
TG (mg/dL) 1.011 (1.008–1.014) < 0.001 1.002 (0.998–1.006) 0.310 1.003 (1.001–1.005) < 0.005
HDL-C (mg/dL) 0.930 (0.915–0.944) < 0.001 0.961 (0.941–0.982) < 0.001 0.966 (0.950–0.983) < 0.001
LDL-C (mg/dL) 1.016 (1.010–1.022) < 0.001 1.002 (0.995–1.010) 0.568 1.001 (0.995–1.007) 0.704
Dyslipidemia 3.382 (2.265–5.048) < 0.001 1.701 (1.044–2.771) < 0.05 0.913 (0.537–1.553) 0.738
FPG (mg/dL) 1.041 (1.028–1.054) < 0.001 1.024 (1.000–1.048) < 0.05 1.005 (0.998–1.012) 0.142
HbA1c (%) 3.376 (2.346–4.860) < 0.001 1.851 (1.064–3.221) < 0.05 1.296 (1.060–1.585) < 0.05
IGT 3.062 (1.901–4.931) < 0.001 1.614 (0.608–4.284) 0.337 1.574 (1.063–2.331) < 0.05
UA (mg/dL) 2.025 (1.748–2.346) < 0.001 1.240 (1.031–1.490) < 0.05 1.315 (1.125–1.536) < 0.001
AST (IU/L) 1.206 (1.173–1.240) < 0.001 1.283 (1.212–1.358) < 0.001 1.243 (1.187–1.301) < 0.001
GGT (IU/L) 1.020 (1.016–1.025) < 0.001 1.030 (1.018–1.041) < 0.001 1.040 (1.029–1.051) < 0.001
FIB-4 index 0.748 (0.491–1.140) 0.173 0.652 (0.382–1.112) 0.652 1.338 (0.883–2.029) 0.170
Smoker 1.620 (0.870–3.015) 0.150 1.239 (0.660–2.328) 0.505 0.802 (0.464–1.385) 0.428
Drinker 0.878 (0.596–1.293) 0.509 1.195 (0.758–1.886) 0.444 0.864 (0.587–1.273) 0.460
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; CI, confidence interval; DBP, diastolic blood pressure; FPG, fasting plasma
glucose; GGT, gamma-glutamyl transpeptidase; HbA1c, hemoglobin A1c; HDL-C, high-density lipoprotein cholesterol; IGT, impaired glucose tolerance; LDL-C, low-
density lipoprotein cholesterol; MS, metabolic syndrome; NAFLD, nonalcoholic fatty liver disease; OR, odds ratio; SBP, systolic blood pressure; T-CHO, total
cholesterol; TG, triglyceride; UA, uric acid; WC, waist circumference. Drinker: < 20 g/day of alcohol in male; < 10 g/day of alcohol in female.
https://doi.org/10.1371/journal.pone.0238388.t002
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without NAFLD having elevation of ALT was significantly higher than that in subjects with
NAFLD having elevation of ALT (p< 0.05). AST, HOMA-IR, and NAFIC scores in subjects
with NAFLD having elevation of ALT were significantly higher than those in subjects without
NAFLD having elevation of ALT (p< 0.001, p< 0.05, and p< 0.005, respectively).
Comparison of primary metabolites between subjects with and without
NAFLD having elevation of ALT in 32 subjects with MS
A comparison of 52 metabolites between subjects with and without NAFLD having elevation
of ALT in 32 subjects with MS are shown in Table 5. There were significant differences in
three of the 52 metabolites between subjects with and without NAFLD having elevation of
ALT. Mean nicotinamide levels in the subjects without NAFLD having elevation of ALT and
subjects with NAFLD having elevation of ALT of ALT were 2.860E-04 ± 1.064E-04 and
3.877E-04 ± 1.284E-04, respectively, which was a statistically significant difference (p< 0.05).
Mean inosine levels in the subjects without NAFLD having elevation of ALT and subjects with
NAFLD having elevation of ALT were 0 and 2.646E-05 ± 4.495E-05, respectively, which was
also a statistically significant difference (p< 0.05). Mean acetyl-L-carnitine levels in the sub-
jects without NAFLD having elevation of ALT and subjects with NAFLD having elevation of
ALT were 1.013E-01 ± 1.947E-02 and 8.699E-02 ± 1.874E-02, respectively, which was also a
statistically significant difference (p< 0.05).
Correlations between clinical parameters and significant metabolites for
NAFLD having elevation of ALT
Spearman rank coefficients for clinical parameters and metabolites with statistically significant
differences between subjects with and without NAFLD having elevation of ALT in MS are
shown in Table 6. Niacinamide levels correlated significantly with ALT, NAFIC score, and
NAFLD having elevation of ALT (p<0.05 for all). Inosine levels correlated significantly with
ALT, HOMA-IR, and NAFLD having elevation of ALT (p< 0.05, p<0.01, and p<0.05,
respectively). Acetyl-L-carnitine levels correlated significantly with IGT and NAFLD having
elevation of ALT (p< 0.05 for both).
Table 3. Results of multivariate analysis for independent predictors of NAFLD having elevation of ALT among Non-MS, Pre-MS, and MS groups.
Non-MS group Pre-MS group MS group
Factor OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value
BMI (kg/m2) 1.358 (1.232–1.496) < 0.001 1.179 (1.059–1.312) < 0.005
Hypertension 0.416 (0.937–1.004) < 0.05
HDL-C (mg/dL) 0.955 (0.934–0.975) < 0.001 0.963 (0.941–0.987) < 0.005
LDL-C (mg/dL) 1.012 (1.005–1.020) < 0.005
HbA1c (%) 2.473 (1.531–3.995) < 0.001
IGT 2.605 (1.469–4.621) < 0.005
UA (mg/dL) 1.315 (1.061–1.631) < 0.05
AST (IU/L) 1.211 (1.171–1.252) < 0.001 1.310 (1.224–1.402) < 0.001 1.240 (1.178–1.305) < 0.001
GGT (IU/L) 1.018 (1.003–1.033) < 0.05 1.021 (1.021–1.033) < 0.001
All the parameters that had a P value of less than 0.05 by univariate analysis were assessed using stepwise multivariate logistic regression analysis adjusted age and
gender.
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; CI, confidence interval; GGT, gamma-glutamyl transpeptidase; HbA1c,
hemoglobin A1c; HDL-C, high-density lipoprotein cholesterol; IGT, impaired glucose tolerance; LDL-C, low-density lipoprotein cholesterol; MS, metabolic syndrome;
NAFLD, nonalcoholic fatty liver disease; OR, odds ratio; UA, uric acid.
https://doi.org/10.1371/journal.pone.0238388.t003
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Comparison of sulfur metabolites between subjects with and without
NAFLD having elevation of ALT in 32 subjects with MS
A comparison of 17 sulfur metabolites that was associated sulfur metabolic pathways between
subjects with and without NAFLD having elevation of ALT in 32 subjects with MS are shown
in Table 7. There were no differences in sulfur metabolites between subjects with and without
NAFLD having elevation of ALT.
Discussion
The aim of the present study was to clarify the differences in clinical factors associated with
NAFLD having elevation of ALT among subjects with Non-MS, Pre-MS, and MS, and to mea-
sure differences in metabolites between MS subjects with and without NAFLD having eleva-
tion of ALT. The present study showed that the prevalence of NAFLD having elevation of ALT
was progressively greater in subjects with Non-MS, Pre-MS, and MS, however, independent
predictors for NAFLD having elevation of ALT differed among subjects with MS, Pre-MS, and
Table 4. Comparison of baseline characteristics between subjects with and without NAFLD having elevation of ALT in 32 subjects with MS.
Subjects without NAFLD having elevation of ALT (n = 14) Subjects with NAFLD having elevation of ALT (n = 18) p-value
Gender (F/M) (%M) 3/11 (78.6%) 6/12 (66.7%) 0.729
Age (years) 57.4 ± 3.1 54.3 ± 4.2 < 0.05
BMI (kg/m2) 27.9 ± 5.0 29.0 ± 5.6 0.372
WC (cm) 95.9 ± 9.9 98.0 ± 11.9 0.447
Smoker, n (%) 2 (14.3%) 4 (22.2%) 0.909
Drinker, n (%) 8 (57.1%) 9 (50.0%) 0.964
SBP (mmHg) 142 ± 24 143 ± 20 0.894
DBP (mmHg) 91 ± 11 97 ± 11 0.098
Hypertension, n (%) 12 (78.6%) 16 (88.9%) 0.788
T-CHO (mg/dL) 210.4 ± 43.4 216.8 ± 45.2 0.447
TG (mg/dL) 154.9 ± 95.3 159.3 ± 124.3 0.849
HDL-C (mg/dL) 61.9 ± 13.0 57.6 ± 11.7 0.333
LDL-C (mg/dL) 128.9 ± 37.6 136.1 ± 45.9 0.531
Dyslipidemia, n (%) 11 (78.6%) 9 (50.0%) 0.198
FPG (mg/dL) 113.4 ± 35.0 107.1 ± 13.5 0.733
HbA1c (%) 6.2 ± 0.9 5.9 ± 0.4 0.608
IGT, n (%) 5 (35.7%) 6 (33.3%) 0.815
UA (mg/dL) 6.2 ± 1.1 5.8 ± 1.9 0.323
AST (IU/L) 23.2 ± 6.3 37.1 ± 11.3 < 0.001
GGT (IU/L) 73.8 ± 136.3 117.9 ± 109.9 < 0.05
HOMA-IR 1.37 ± 0.68 2.14 ± 1.22 < 0.05
NAFIC score 0.00 ± 0.00 0.78 ± 0.94 < 0.005
FIB-4 index 1.24 ± 0.46 1.29 ± 0.43 0.536
Data represent the mean ± standard deviation (SD) and number for categorical variables. All p-values are based on the χ2-test or Mann-Whitney U-test. Significant is at
the 5% level.
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; DBP, diastolic blood pressure; F, female; FPG, fasting plasma glucose; GGT,
gamma-glutamyl transpeptidase; HbA1c, hemoglobin A1c; HDL-C, high-density lipoprotein cholesterol; HOMA-IR, homeostasis model assessment of insulin
resistance; IGT, impaired glucose tolerance; LDL-C, low-density lipoprotein cholesterol; M, male; MS, metabolic syndrome; NAFLD, nonalcoholic fatty liver disease;
SBP, systolic blood pressure; T-CHO, total cholesterol; TG, triglyceride; UA, uric acid; WC, waist circumference. Drinkers: < 20 g/day of alcohol in male; < 10 g/day of
alcohol in female.
https://doi.org/10.1371/journal.pone.0238388.t004
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Table 5. Comparison of 52 metabolites between subjects with and without NAFLD having elevation of ALT in 32 subjects with MS.
Compound name Relative area
Subjects without NAFLD having elevation of ALT
(n = 14)
Subjects with NAFLD having elevation of ALT
(n = 18)
p-value
Mean SD Mean SD
Cystine 1.082E-03 2.017E-04 1.028E-03 1.389E-04 0.640
Asparagine 7.745E-05 3.984E-05 8.506E-05 3.484E-05 0.536
Aspartic acid 4.126E-04 1.326E-04 4.189E-04 8.649E-05 0.750
Serine 7.230E-04 1.622E-04 7.298E-04 1.319E-04 0.808
Alanine 1.947E-02 6.607E-03 2.286E-02 4.579E-03 0.116
4-Hydroxyproline 3.433E-04 1.358E-04 4.301E-04 1.588E-04 0.206
Glycine 4.413E-04 9.391E-05 4.494E-04 8.944E-05 0.750
Citicoline 7.903E-06 1.404E-05 1.063E-05 1.979E-05 0.911
Glutamine 2.953E-02 3.410E-03 3.088E-02 4.163E-03 0.377
Threonine 3.439E-03 7.568E-04 3.491E-03 8.851E-04 0.837
Dimethylglycine 4.708E-03 1.097E-03 4.651E-03 8.881E-04 0.750
Methionine sulfoxide 1.046E-04 4.747E-05 9.511E-05 3.397E-05 0.319
Glutamic acid 3.490E-03 1.746E-03 3.623E-03 1.366E-03 0.694
Citrulline 7.294E-03 1.317E-03 6.693E-03 8.798E-04 0.135
Guanosine 3.967E-06 1.484E-05 2.479E-07 1.052E-06 0.851
monophosphate
Proline 2.485E-01 4.956E-02 2.753E-01 8.652E-02 0.442
Ornithine 4.251E-03 1.102E-03 4.110E-03 9.098E-04 0.750
2-Aminobutyric acid 1.918E-02 5.096E-03 2.011E-02 7.018E-03 0.955
Lysine 3.186E-02 3.671E-03 3.258E-02 4.485E-03 0.694
Histidine 9.708E-03 1.656E-03 1.042E-02 1.969E-03 0.420
Adenosine 4.911E-04 2.127E-04 6.759E-04 3.769E-04 0.206
monophosphate
Uracil 3.357E-04 1.014E-04 3.380E-04 1.211E-04 0.925
Argininosuccinic acid 4.759E-06 1.781E-05 1.811E-06 5.311E-06 0.792
Thymidine 3.525E-04 3.950E-05 3.977E-04 7.492E-05 0.125
monophosphate
Arginine 5.495E-02 1.148E-02 5.614E-02 9.900E-03 0.512
Creatine 3.491E-02 1.206E-02 3.948E-02 1.639E-02 0.587
Cytosine 2.301E-05 3.634E-05 1.278E-05 1.807E-05 0.606
Hypoxanthine 6.302E-04 1.968E-04 5.695E-04 2.767E-04 0.357
Uridine 5.871E-03 1.262E-03 6.104E-03 1.281E-03 0.377
Niacinamide 2.860E-04 1.064E-04 3.877E-04 1.284E-04 < 0.05
Adenosine 3’,5’-cyclic 1.437E-05 2.063E-05 1.015E-05 2.065E-05 0.638
monophosphate
Guanosine 0 NA 6.817E-06 1.730E-05 0.165
Inosine 0 NA 2.646E-05 4.495E-05 < 0.05
Pantothenic acid 1.674E-04 8.621E-05 1.582E-04 7.059E-05 0.955
Adenine 4.656E-05 3.952E-05 4.169E-05 2.024E-05 0.849
Tyrosine 8.111E-02 1.878E-02 8.979E-02 1.276E-02 0.235
Adenosine 8.633E-06 1.771E-05 1.784E-05 3.288E-05 0.582
Epinephrine 9.644E-05 3.229E-05 9.507E-05 2.436E-05 0.985
Asymmetric 2.457E-06 9.195E-06 0 NA 0.415
dimethylarginine
(Continued)
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Non-MS. Additionally, there were significant differences in levels of several metabolites between
subjects with and without NAFLD having elevation of ALT in spite of the subjects who belong to
same MS. To our knowledge, ours is the first study to clarify the differences in subjects with
Table 5. (Continued)
Compound name Relative area
Subjects without NAFLD having elevation of ALT
(n = 14)
Subjects with NAFLD having elevation of ALT
(n = 18)
p-value
Mean SD Mean SD
Phenylalanine 7.267E-01 9.136E-02 7.492E-01 7.121E-02 0.267
Kynurenine 4.298E-03 8.353E-04 4.559E-03 9.591E-04 0.808
Acetyl-L-carnitine 1.013E-01 1.947E-02 8.699E-02 1.874E-02 < 0.05
Tryptophan 2.859E-01 5.521E-02 2.990E-01 4.335E-02 0.357
2-Ketoglutaric acid 3.563E-04 1.234E-04 3.979E-04 8.680E-05 0.091
Malic acid 5.997E-04 1.276E-04 6.457E-04 1.697E-04 0.640
Isocitric acid 3.879E-03 8.329E-04 4.398E-03 7.126E-04 0.067
Pyruvic acid 1.951E-04 1.178E-04 2.225E-04 1.234E-04 0.362
Lactic acid 1.959E-02 5.195E-03 1.832E-02 4.893E-03 0.442
Uric acid 1.208E-02 1.914E-03 1.146E-02 2.774E-03 0.536
Citric acid 4.857E-02 5.312E-03 5.251E-02 5.954E-03 0.107
Succinic acid 2.037E-04 1.572E-04 1.987E-04 1.424E-04 1.000
Xanthine 1.058E-05 2.699E-05 7.473E-05 2.926E-04 0.675
P-value is based on Mann-Whitney U-test. Significant is at the 5% level. Peak areas of individual metabolites were normalized against the peak area of the internal
standards, and the resulting values were represented as relative areas.
ALT, alanine aminotransferase; MS, metabolic syndrome; NA, not applicable; NAFLD, nonalcoholic fatty liver disease, NS, not significant; SD, standard deviation.
https://doi.org/10.1371/journal.pone.0238388.t005
Table 6. Spearman rank coefficients for clinical parameters and metabolites those showed a statistically significant difference between subjects with and without
NAFLD having elevation of ALT in MS.
Niacinamide Inosine Acetylcarnitine
BMI -0.001 0.181 -0.016
WC -0.082 0.182 -0.027
Hypertension -0.021 0.180 0.113
Dyslipidemia -0.091 -0.227 0.189
IGT -0.132 -0.173 0.445�
ALT 0.368� 0.374� -0.252
AST 0.302 0.253 -0.259
GGT 0.151 -0.276 -0.079
UA -0.133 -0.018 0.101
HOMA-IR 0.269 0.472�� -0.222
NAFIC score 0.350� 0.189 -0.207
FIB-4 index 0.120 0.060 -0.310
Fatty liver 0.113 0.229 0.113
NAFLD with elevation of ALT 0.368� 0.421� -0.355�
�p< 0.05
��p< 0.01.
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; GGT, gamma-glutamyl transpeptidase; HOMA-IR: homeostasis model
assessment of insulin resistance; IGT, impaired glucose tolerance; MS, metabolic syndrome; NAFLD, nonalcoholic fatty liver disease; UA, uric acid; WC, waist
circumference.
https://doi.org/10.1371/journal.pone.0238388.t006
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NAFLD having elevation of ALT at various stage of MS, as well as measuring differences in
metabolites with respect to NAFLD having elevation of ALT in the context of medical check-ups.
We demonstrated that values of physical measurements such as BMI and WC, and almost
factors related to hypertension, dyslipidemia, and IGT were progressively greater in the Non-
MS, Pre-MS, MS groups, in accordance with previous reports that BMI, WC, blood pressure,
HOMA-IR, and others increased with the number of MS components [17–19]. Liver enzymes
such as ALT and AST, and the prevalence of NAFLD and NAFLD having elevation of ALT
increased with progression from Non-MS to Pre-MS to MS. These results suggest that the onset
of NAFLD and elevation of liver enzyme were strongly associated with MS components such as
obesity, including visceral fat and lifestyle-related diseases. Furthermore, the prevalence of
NAFLD and NAFLD having elevation of ALT among subjects except the MS group were 25.3%
and 8.4%, respectively. This prevalence was not low, and we cannot ignore this fact.
We showed that independent predictors of NAFLD having elevation of ALT varied among
Non-MS, Pre-MS, and MS groups. The prevalence of dyslipidemia and IGT in the Non-MS
group was lower than that of the MS group; however, LDL, HbA1c, and UA were significant
factors of NAFLD having elevation of ALT in the Non-MS group. These results suggest that,
even in non-obese individuals, paying attention to dyslipidemia and IGT is necessary. Hyper-
uricemia is associated with an elevated risk of developing impaired fasting glucose [20]. IGT
due to insulin resistance may lead to hyperinsulinemia, which increases uric acid concentra-
tions by reducing renal uric acid secretion and accumulating substrates for uric acid produc-
tion [21, 22]. Hyperuricemia was reported to be associated with histological liver damage in
Table 7. Comparison of 17 sulfur metabolites between subjects with and without NAFLD having elevation of ALT in 32 subjects with MS.
Compound name Relative area
Subjects without NAFLD having elevation of ALT
(n = 14)
Subjects with NAFLD having elevation of ALT
(n = 18)
p-value
Mean SD Mean SD
Glucose 2.52E-03 4.43E-04 2.49E-03 4.61E-04 0.896
Methionine 7.67E-04 2.27E-04 8.10E-04 3.58E-04 0.640
Serine 0 NA 2.83E-04 1.20E-03 0.526
Histidine 6.06E-03 9.06E-04 5.94E-03 1.16E-03 0.694
Cys-bimane 1.37E-03 1.80E-04 1.51E-03 4.48E-04 0.613
Cys-S-bimane 1.18E-03 3.86E-04 1.06E-03 4.41E-04 0.283
GS-bimane 7.00E-05 5.69E-05 6.70E-05 5.60E-05 0.675
GS-S-bimane 3.47E-06 1.30E-05 1.79E-06 7.60E-06 0.851
Sulfite-bimane 1.69E-04 2.18E-04 1.26E-04 5.67E-05 0.955
SDB 8.70E-03 5.58E-03 8.67E-03 3.77E-03 0.319
Thiosulfate-bimane 2.59E-02 1.43E-02 2.52E-02 1.36E-02 0.955
Ergothioneine-bimane 2.30E-02 9.88E-03 2.43E-02 1.11E-02 0.750
Cystathionine 3.88E-04 8.51E-05 3.99E-04 8.46E-05 0.925
GSSG [M+2H]2+ 3.10E-05 3.20E-05 2.85E-05 3.33E-05 0.877
Ergothioneine 3.68E-05 1.38E-04 0 NA 0.415
S-sulfocysteine 1.98E-06 5.23E-06 0 NA 0.177
Lactic acid 1.17E-02 3.02E-03 1.17E-02 3.10E-03 0.894
P-value is based on Mann-Whitney U-test. Significant is at the 5% level. Peak areas of individual metabolites were normalized against the peak area of the internal
standards, and the resulting values were represented as relative areas.
ALT, alanine aminotransferase; Cys, cysteine; GS, glutathione; GSSG [M+2H]2+, glutathione oxide sulfide; MS, metabolic syndrome; NA, not applicable; NAFLD,
nonalcoholic fatty liver disease; NS, not significant; S, sulfide; SD, standard deviation; SDB, sulfide dibimane.
https://doi.org/10.1371/journal.pone.0238388.t007
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patients with NAFLD [23]. These findings suggest that our study might indicate that not only
HbA1c but also UA are significant risk factors for NAFLD having elevation of ALT in the
Non-MS group.
In the MS group, IGT was a significant independent predictor of an increase prevalence of
NAFLD having elevation of ALT in accordance with previous reports that DM and insulin
resistance are associated with NAFLD [24, 25]. Obesity and visceral adipose tissue are risk fac-
tors for insulin resistance. In particular, excessive visceral fat accumulation releases various
bioactive substances known as inflammatory adipokines, include interleukin-6, tumor necrosis
factor-α, macrophage chemoattractant protein-1, and resistin [26, 27]. Therefore, visceral fat
accumulation is thought to play an important role in the development of NAFLD [28–33].
These findings support our result that the prevalence of NAFLD and NAFLD having elevation
of ALT in MS group were higher than in other groups.
Conversely, HDL-C was a significant independent predictor of decreased risk for NAFLD
having elevation of ALT in the Non-MS and MS groups. Levels of TG, IGT, and HDL-C were
significantly different between subjects with and without NAFLD having elevation of ALT in
the Non-MS and MS groups. NAFLD is strongly associated with dyslipidemia, including
decreased HDL-C levels and increased TG levels [34, 35]. TG is synthesized from free fatty
acids. Excess energy, decreased lipolysis in adipose tissue, increased lipogenesis in the liver,
and insulin resistance that suppresses lipolysis and increases de novo lipogenesis may induce
increased free fatty acid levels [36–38]. The main component of very low-density lipoprotein
(VLDL) in liver is TG, and increased VLDL and IGT in diabetes causes decreased HDL-C lev-
els [39]. Therefore, our study might show that HDL is a significant independent predictor of
decreased prevalence of NAFLD having elevation of ALT.
In the Pre-MS group, hypertension was a significant independent predictor of decreased
prevalence of NAFLD having elevation of ALT. However, there was no significant difference
in the prevalence of NAFLD having elevation of ALT between subjects without hypertension
and subjects having hypertension without medication. In recent reports, angiotensin II recep-
tor blockers may suppress liver fibrosis with NAFLD including non-alcoholic steatohepatitis
[40–42]. Our results might be affected by use of antihypertensive agents. Further studies are
needed to elucidate the association between NAFLD and antihypertensive agents because we
did not investigate the type of antihypertensive agents.
Metabolomics involves the measurement of large numbers of low-molecular-weight
metabolites, including sugars, amino acids, and hormones. Although several studies have
provided insight into the pathogenesis of NAFLD [43–46], to date, no specific biomarker
that could identify NAFLD has been found using metabolomics. We found that the levels of
metabolites such as inosine and nicotinamide were significantly higher in subjects with
NAFLD having elevation of ALT than those in subjects without NAFLD having elevation of
ALT. Inosine is found in meat and is an organic compound with a nucleoside-like structure.
Consuming large amounts of food containing inosine may increase uric acid levels because
inosine is metabolized to uric acid. The elevation of uric acid levels is associated with
NAFLD in several cohort studies [47, 48]. Nicotinamide is a B-complex vitamin that partici-
pates in energy production and metabolism of sugar, lipids, and proteins as a coenzyme of
dehydrogenase. High dietary intake of nicotinamide is unfavorable because the accumula-
tion of nicotinamide may cause liver dysfunction [49]. This suggests that elevated serum lev-
els of inosine and nicotinamide may be associated with NAFLD. Conversely, acetyl-L-
carnitine levels were significantly lower in subjects with NAFLD having elevation of ALT
than those in subjects without NAFLD having elevation of ALT in our study. Acetyl-L-carni-
tine is an acetylated derivative of L-carnitine that participates in oxidative metabolism.
Decreased L-carnitine levels were associated with insulin resistance and L-carnitine
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supplementation in rats and mice improved metabolic function and NAFLD [50, 51]. Our
findings suggest that lower levels of acetyl-L-carnitine may be associated with NAFLD.
Recently, reactive sulfur species (RSS) have been recognized to be endogenously produced in
abundance in many species [52, 53]. They occur in diverse polysulfide forms with unique
redox-active or reactive chemical properties [54–56]. Sulfur metabolomics was developed to
investigate the sulfur metabolic pathways associated with RSS [52, 53, 57]. Although there
was no sulfur metabolite that showed statistically significantly different levels between sub-
jects with and without NAFLD having elevation of ALT in our study, the additional results
showed that there was a tendency of difference in levels of S-sulfocysteine between subjects
having NAFLD with normal ALT levels and those having NAFLD with elevation of ALT lev-
els (p = 0.072, S1 Table). Although the influence of S-sulfocysteine on the liver is unclear,
there is a possibility that sulfites and its derivatives induce oxidative stress [58, 59] and dis-
turb mitochondrial function in rat experiments [60, 61]. Metabolomics in our study identi-
fied three metabolites that were significantly correlated with NAFLD having elevation of
ALT, and one sulfur metabolite had the possibility of differentiating between subjects having
NAFLD with elevation of ALT levels and those having NAFLD with normal ALT levels.
These results suggest that metabolomics may become a useful screening test for NAFLD in
individuals with MS during medical check-ups in the future.
Although the HOMA-IR and NAFIC scores effectively discriminated between subjects with
and without NAFLD having elevation of ALT in our study, they were within the range of nor-
mal in almost all subjects. Therefore, not only persons whose HOMA-IR or NAFIC scores are
high but also those whose HOMA-IR or NAFIC scores are within standard values should be
carefully assessed during medical check-ups.
The present study had several limitations. First, it was a single-center study, and therefore
may be subject to selection bias. For this reason, we instituted strict inclusion and exclusion
criteria. Multi-center studies are needed to validate our findings. Second, different results may
be found in patients who go to the hospital for NAFLD and those who are found to have
NAFLD during medical check-ups because most of the participants in the present study were
healthy individuals without symptoms. Further investigations of the differences between these
groups are required. Third, we did not obtain information regarding treatments for hyperten-
sion and DM, diets (e.g., volume and contents including vegetable and fruits), and total caloric
intake. Finally, the number of subjects who were investigated regarding metabolomics was
small because metabolomics is not usually included in medical check-ups. Further studies are
necessary to resolve these limitations.
In conclusion, we demonstrated that the prevalence of NAFLD having elevation of ALT
was progressively higher in Non-MS, Pre-MS and MS groups. Significant independent predic-
tors for NAFLD having elevation of ALT were different among the three groups. Not only
liver scoring systems such as the HOMA-IR and NAFIC score but also several metabolites may




S1 Table. Comparison of 17 sulfur metabolites between subjects with NAFLD having eleva-
tion of ALT and subjects with NAFLD having standard values of ALT in 26 subjects with
MS.
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